Company news

Immuron Limited news in 2019

Immuron Limited's news releases, calls and decks from 2019, newest first.

View company

Immuron Plans IMM-124E Trial to Prevent Travelers Diarrhea

November 20, 2019

Immuron Receives AUD $0.53M R&D Tax Concession Refund

November 3, 2019

Immuron North American Q1 Sales Up 111% YoY

October 13, 2019

US Defense funds AU$5.5M for Immuron New Gastro Weapon

October 1, 2019

US Defense Reports Immuron Travelan Targets Cholera

September 3, 2019

Appendix 4E & Annual Report to shareholders

August 30, 2019

Immuron Reports Results in SAH Clinical Trial

August 7, 2019

Underwritten Public Offer

July 17, 2019

Immuron Prices Underwritten Public Offering of ADSs

July 17, 2019

Proposed Public Offer of IMRN ADSs

July 16, 2019

Immuron North American revenue surges by 52% in FY19

July 16, 2019

US DoD Reports Results from Travelan Shigellosis Study

June 12, 2019

Preliminary Prospectus Supplement filed with SEC

May 24, 2019

Trading halt

May 23, 2019

Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors

April 16, 2019

Immuron sales surge by 66% in the Third Quarter of FY19

April 14, 2019

Immuron Aims to Secure FDA Approval for IMM-124E

April 10, 2019

Company Update on CDI Clinical Trial and New Strategic Focus

March 18, 2019

Travelan FY19 Update and Expansion into North America

January 28, 2019

Form F-3

January 14, 2019

Immuron Receives $1.19M R&D Tax Concession Refund

January 2, 2019

Decks in 2019